Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Patients (PTS) with Metastatic or Surgically Unresectable (M/UR) Urothelial Carcinoma (UC) and Selected FGFR Gene Alterations (FGFRALT): Phase 3 THOR Study

被引：0

作者：

Imkamp, Florian ^{[1
]}

Loriot, Yohann ^{[2
]}

Necchi, Andrea ^{[3
]}

Park, Se Hoon ^{[4
]}

Huddart, Robert ^{[5
]}

Burgess, Earle ^{[6
]}

Fu, Min ^{[7
]}

Santiago-Walker, Ademi ^{[7
]}

Mukhopadhyay, Sutapa ^{[7
]}

Naini, Vahid ^{[7
]}

Deprince, Kris ^{[8
]}

Monga, Manish ^{[7
]}

Siefker-Radtke, Arlene ^{[9
]}

机构：

[1] Hannover Univ, Dept Urol, Med Ctr, Hannover, Germany

[2] Inst Gustave Roussy, Villejuif, France

[3] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[4] Samsung Med Ctr, Seoul, South Korea

[5] Inst Canc Res, London, England

[6] Carolinas HealthCare Syst, Levine Canc Inst, Charlotte, NC USA

[7] Janssen Res & Dev, San Diego, CA USA

[8] Janssen Res & Dev, Beerse, Belgium

[9] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

488

引用

页码：78 / 78

页数：1

共 36 条

[1] Erdafitinib compared with vinflunine or docetaxel or pembrolizumab in patients (pts) with metastatic or surgically unresectable (M/UR) urothelial carcinoma (UC) and selected fgfr gene alterations (FGFRalt): The phase III THOR study
Loriot, Y.
Necchi, A.
Park, S. H.
Huddart, R. A.
Burgess, E.
Zhong, B.
Santiago-Walker, A.
Little, S.
Roccia, T.
De Porre, P.
Siefker-Radtke, A. O.
ANNALS OF ONCOLOGY, 2018, 29
[2] Second or Third Line Therapy of unresectable or metastatic Urothelial Carcinoma Phase 3 Study of Erdafitinib versus Vinflunine or Docetaxel or Pembrolizumab in Patients with advanced Urothelial Carcinoma and Alterations in the FGFR Genes. (THOR) - AB 79/21 of the AUO
Rexer, H.
Peters, I.
Retz, M.
UROLOGIE, 2022, 61 (08): : 915 - 916
[3] Ongoing phase 2 study of erdafitinib (JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (M/UR UC) and FGFR gene alterations
Siefker-Radtke, A. O.
Mellado, B.
Decaestecker, K.
Burke, J. M.
O'Hagan, A.
Avadhani, A.
Zhong, B.
Santiago-Walker, A.
De Porre, P.
Brookman-May, S.
Garcia-Donas, J.
ANNALS OF ONCOLOGY, 2016, 27
[4] Erdafitinib (erda) vs chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select FGFR alterations (FGFRalt): Subgroups from the phase III THOR study
Loriot, Y.
Matsubara, N.
Huddart, R. A.
Houede, N.
Laguerre, B.
Guadalupi, V.
Ku, J. H.
Triantos, S.
Akapame, S.
Deprince, K.
Mukhopadhyay, S.
Siefker-Radtke, A. O.
ANNALS OF ONCOLOGY, 2023, 34 : S1201 - S1201
[5] First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt).
Siefker-Radtke, Arlene O.
Necchi, Andrea
Park, Se Hoon
GarcAa-Donas, JesAs
Huddart, Robert A.
Burgess, Earle Frederick
Fleming, Mark T.
Rezazadeh, Arash
Mellado, Begona
Varlamov, Sergei
Joshi, Monika
Duran, Ignacio
Tagawa, Scott T.
OHagan, Anne
Avadhani, Anjali Narayan
Zhong, Bob
De Porre, Peter
Loriot, Yohann
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[6] Phase III THOR study: Results of erdafitinib (erda) vs pembrolizumab (pembro) in pretreated patients (pts) with advanced or metastatic urothelial cancer (muc) with select fibroblast growth factor receptor alterations (FGFRalt)
Siefker-Radtke, A. O.
Matsubara, N.
Park, S. H.
Huddart, R. A.
Burgess, E. F.
Ozguroglu, M.
Perez Valderrama, B.
Triantos, S.
Akapame, S.
Kean, Y.
Deprince, K.
Mukhopadhyay, S.
Loriot, Y.
ANNALS OF ONCOLOGY, 2023, 34 : S1199 - S1199
[7] Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt)
Loriot, Yohann
Matsubara, Nobuaki
Park, Se Hoon
Huddart, Robert A.
Burgess, Earle F.
Houede, Nadine
Banek, Severine
Laguerre, Brigitte
Guadalupi, Valentina
Ku, Ja Hyeon
Triantos, Spyros
Akapame, Sydney
Deprince, Kris
Mukhopadhyay, Sutapa
Siefker-Radtke, Arlene O.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
[8] Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt)
Banek, S.
Loriot, Y.
Matsubara, N.
Park, S. H.
Huddart, R. A.
Burgess, E. F.
Houede, N.
Laguerre, B.
Guadalupi, V
Ku, J. H.
Triantos, S.
Akapame, S.
Deprince, K.
Mukhopadhyay, S.
Siefker-Radtke, A. O.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 94 - 94
[9] Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt).
Matsubara, Nobuaki
Park, Se Hoon
Huddart, Robert A.
Burgess, Earle F.
Houede, Nadine
Banek, Severine
Laguerre, Brigitte
Guadalupi, Valentina
Ku, Ja Hyeon
Triantos, Spyros
Akapame, Sydney
Deprince, Kris
Mukhopadhyay, Sutapa
Siefker-Radtke, Arlene O.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA4619 - LBA4619
[10] Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial
Siefker-Radtke, A. O.
Matsubara, N.
Park, S. H.
Huddart, R. A.
Burgess, E. F.
Ozguroglu, M.
Valderrama, B. P.
Laguerre, B.
Basso, U.
Triantos, S.
Akapame, S.
Kean, Y.
Deprince, K.
Mukhopadhyay, S.
Loriot, Y.
ANNALS OF ONCOLOGY, 2024, 35 (01) : 107 - 117

← 1 2 3 4 →